LUND, Sweden, Feb. 5, 2019
LUND, Sweden, Feb. 5, 2019 BioInvent International AB (OMXS: BINV) announces today that its Chief Scientific Officer, Björn Frendéus, will hold a presentation about its phenotypic discovery platform F.I.R.S.T.™ at the Society for Laboratory Automation and Screening (SLAS) 2019 meeting in Washington, D.C. for professionals in the life science industry.
Identification of novel targets, pathways and drugs to help boost activity of and overcome resistance to currently available drugs provide a formidable challenge to improve cancer patient survival. BioInvent has developed F.I.R.S.T.TM, which uses primary patient cells, immune competent- and humanized experimental models, and a human recombinant antibody library, to identify clinically relevant target-antibody pairs in an integrated manner.
"It is a great pleasure and privilege to be invited to explain our unique discovery platform to so many distinguished industry colleagues at SLAS2019," says Björn Frendéus, CSO of BioInvent. "This talk will introduce and exemplify how F.I.R.S.T.TM has been used to successfully identify multiple target-antibody pairs that modulate key pathways critical to overcome immune suppression in the tumor microenvironment. The focus will be on complementary strategies to identify novel Treg pathways, and overcoming antibody drug resistance."
The fully integrated patient-centric drug discovery platform combines an unbiased translational discovery approach with patient primary cells and immune-competent animal models. The technology platform consists of the n-CoDeR® antibody library and the F.I.R.S.T.TM development tool. The platform has been validated by Pfizer and is used in a collaboration program focused on tumor-associated myeloid cells.
Track: Biologics Discovery
Session: Phenotypic selections and novel assays to enable biologics discovery (10:30 AM – 12:30 PM)
Tuesday, February 5, 2019
10:30 AM – 11:00 AM (EST)
Notes to editors:
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206, is currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's exciting pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information, please contact:
Martin Welschof, CEO
Hans Herklots, LifeSci Advisors
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)